Inhibitors of UDP-G1cNAc:Ga1.beta.1-3Ga1NAc.alpha.R .beta.1-6 N-acetylglucosaminyltransferase (core 2 G1cNAc-T) and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes
US6131578A · kind A · utility
6Cited by
0References
10Claims
0Family size
Inventors
Key dates
| Filing date | Oct 2, 1997 |
| Grant date | Oct 17, 2000 |
| Priority date | — |
| Expiry date | Oct 2, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cardiomyopathy associated with diabetes and hyperglycemia can be treated by administering to a subject suffering from this condition a substance that inhibits UDP-GlcNAc:Gal.beta.1-3GalNAc.alpha.R.beta.1-6-N-acetylglucosaminyl transferase (core 2 GlcNAc-T) activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.